

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6597204/publications.pdf>

Version: 2024-02-01

21  
papers

1,348  
citations

759233

12  
h-index

713466

21  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1371  
citing authors

#	ARTICLE	IF	CITATIONS
1	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet</i> , The, 2018, 391, 2335-2345.	13.7	526
2	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1444-1451.	13.7	351
3	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019, 139, 2542-2553.	1.6	97
4	Contemporary Arterial Access in the Cardiac Catheterization Laboratory. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2233-2241.	2.9	82
5	Clinical Characteristics and Outcomes of STEMI Patients With Cardiogenic Shock and Cardiac Arrest. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1211-1219.	2.9	56
6	Meta-analysis of the impact of successful chronic total occlusion percutaneous coronary intervention on left ventricular systolic function and reverse remodeling. <i>Journal of Interventional Cardiology</i> , 2018, 31, 562-571.	1.2	47
7	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2922-2933.	2.9	47
8	Recent advances in microcatheter technology for the treatment of chronic total occlusions. <i>Expert Review of Medical Devices</i> , 2019, 16, 267-273.	2.8	25
9	Accessory renal arteries: Prevalence in resistant hypertension and an important role in nonresponse to radiofrequency renal denervation. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 470-473.	0.8	16
10	Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 32-38.	1.7	15
11	Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation. <i>Hypertension</i> , 2021, 77, 529-536.	2.7	15
12	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2022, 36, 629-639.	2.2	14
13	Coronary Intravascular Brachytherapy for Recurrent Coronary Drug-Eluting Stent In-Stent Restenosis: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 23, 28-35.	0.8	13
14	Prevalence, Trends, and Outcomes of Higher-Risk Percutaneous Coronary Interventions Among Patients Without Acute Coronary Syndromes. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 289-292.	0.8	9
15	Outcomes With Combined Laser Atherectomy and Intravascular Brachytherapy in Recurrent Drug-Eluting Stent In-Stent Restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 22, 29-33.	0.8	7
16	Expecting the unexpected: preventing and managing the consequences of coronary perforations. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 805-814.	1.5	6
17	Challenges and outcomes of the double kissing crush stenting technique: Insights from the PROGRESS-BIFURCATION registry. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1038-1044.	1.7	6
18	Multidisciplinary shock team is associated with improved outcomes in patients undergoing ECPR. <i>International Journal of Artificial Organs</i> , 2021, 44, 310-317.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Impact of sleep deprivation on the outcomes of percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2018, 92, 1118-1125.	1.7	4
20	Coronary revascularization and use of hemodynamic support in acute coronary syndromes. Hellenic Journal of Cardiology, 2019, 60, 165-170.	1.0	4
21	Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO Trial. Cardiovascular Revascularization Medicine, 2022, 39, 58-65.	0.8	3